RESUMO
BACKGROUND: Contrast induced nephropathy (CIN) is the commonest cause of iatrogenic renal injury and its incidence has increased with the advent of complex endovascular procedures. Evidence suggests that ascorbic acid (AA) has a nephroprotective effect in percutaneous coronary interventions when contrast media are used. A variety of biomarkers (NGAL, NGAL:creatinine, mononuclear cell infiltration, apoptosis and RBP-4) in both the urine and kidney were assayed using a mouse model of CIN in order to determine whether AA can reduce the incidence and/or severity of renal injury. METHODS: Twenty-four BALB/c mice were divided into 4 groups. Three groups were exposed to high doses of contrast media (omnipaque) in a well-established model of CIN, and then treated with low or high dose AA or placebo (saline). CIN severity was determined by measurement of urinary neutrophil gelatinase-associated lipocalin (NGAL):creatinine at specific time intervals. Histological analysis was performed to determine the level of mononuclear inflammatory infiltration as well as immunohistochemistry to determine apoptosis in the glomeruli by staining for activated caspase-3 and DNA nicking (TUNEL assays). Reverse transcriptase PCR (rtPCR) of mRNA transcripts prepared from mRNA extracted from mouse kidneys was also performed for both lipocalin-2 (Lcn2) encoding NGAL and retinol binding protein-6 (RBP4) genes. NGAL protein expression was also confirmed by ELISA analysis of kidney lysates. RESULTS: Urinary NGAL:creatinine ratio was significantly lower at 48 h with a 44% and 62% (204.3µg/mmol versus 533.6µg/mmol, p = 0.049) reduction in the low and high dose AA groups, respectively. The reduced urinary NGAL:creatinine ratio remained low throughout the time period assessed (up to 96 h) in the high dose AA group. In support of the urinary analysis ELISA analysis of NGAL in kidney lysates also showed a 57% reduction (12,576 ng/ml versus 29,393 ng/ml) reduction in the low dose AA group. Immunohistochemistry for apoptosis demonstrated decreased TUNEL and caspase-3 expression in both low and high dose AA groups. CONCLUSIONS: Ascorbic acid reduced the frequency and severity of renal injury in this murine model of CIN. Further work is required to establish whether AA can reduce the incidence of CIN in humans undergoing endovascular procedures.
Assuntos
Injúria Renal Aguda/induzido quimicamente , Antioxidantes/farmacologia , Ácido Ascórbico/farmacologia , Meios de Contraste/toxicidade , Iohexol/toxicidade , Rim/efeitos dos fármacos , Injúria Renal Aguda/metabolismo , Animais , Apoptose/efeitos dos fármacos , Caspase 3/efeitos dos fármacos , Caspase 3/metabolismo , Creatinina/urina , Modelos Animais de Doenças , Procedimentos Endovasculares , Imuno-Histoquímica , Marcação In Situ das Extremidades Cortadas , Rim/metabolismo , Rim/patologia , Lipocalina-2/efeitos dos fármacos , Lipocalina-2/metabolismo , Lipocalina-2/urina , Camundongos , Camundongos Endogâmicos BALB C , Proteínas Plasmáticas de Ligação ao Retinol/efeitos dos fármacos , Proteínas Plasmáticas de Ligação ao Retinol/metabolismoRESUMO
NAD metabolism regulates diverse biological processes, including ageing, circadian rhythm and axon survival. Axons depend on the activity of the central enzyme in NAD biosynthesis, nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2), for their maintenance and degenerate rapidly when this activity is lost. However, whether axon survival is regulated by the supply of NAD or by another action of this enzyme remains unclear. Here we show that the nucleotide precursor of NAD, nicotinamide mononucleotide (NMN), accumulates after nerve injury and promotes axon degeneration. Inhibitors of NMN-synthesising enzyme NAMPT confer robust morphological and functional protection of injured axons and synapses despite lowering NAD. Exogenous NMN abolishes this protection, suggesting that NMN accumulation within axons after NMNAT2 degradation could promote degeneration. Ectopic expression of NMN deamidase, a bacterial NMN-scavenging enzyme, prolongs survival of injured axons, providing genetic evidence to support such a mechanism. NMN rises prior to degeneration and both the NAMPT inhibitor FK866 and the axon protective protein Wld(S) prevent this rise. These data indicate that the mechanism by which NMNAT and the related Wld(S) protein promote axon survival is by limiting NMN accumulation. They indicate a novel physiological function for NMN in mammals and reveal an unexpected link between new strategies for cancer chemotherapy and the treatment of axonopathies.
Assuntos
Axônios/metabolismo , Degeneração Neural/metabolismo , Mononucleotídeo de Nicotinamida/metabolismo , Traumatismos dos Nervos Periféricos/metabolismo , Amidoidrolases/farmacologia , Animais , Axônios/patologia , Proteínas de Bactérias/farmacologia , Camundongos , Degeneração Neural/tratamento farmacológico , Degeneração Neural/genética , Degeneração Neural/patologia , Nicotinamida-Nucleotídeo Adenililtransferase/metabolismo , Traumatismos dos Nervos Periféricos/tratamento farmacológico , Traumatismos dos Nervos Periféricos/genética , Traumatismos dos Nervos Periféricos/patologiaRESUMO
Axon degeneration is an early event in many neurodegenerative disorders. In some, the mechanism is related to injury-induced Wallerian degeneration, a proactive death program that can be strongly delayed by the neuroprotective slow Wallerian degeneration protein (Wld(S)) protein. Thus, it is important to understand the Wallerian degeneration mechanism and how Wld(S) blocks it. Wld(S) location is influenced by binding to valosin-containing protein (VCP), an essential protein for many cellular processes including membrane fusion and endoplasmic reticulum-associated degradation. In mice, the N-terminal 16 amino acids (N16), which mediate VCP binding, are essential for Wld(S) to protect axons, a role which another VCP binding sequence can substitute. In Drosophila, the Wld(S) phenotype is weakened by a similar N-terminal truncation and by knocking down the VCP homologue ter94. Neither null nor floxed VCP mice are viable so it is difficult to confirm the requirement for VCP binding in mammals in vivo. However, the hypothesis can be tested further by introducing a Wld(S) missense mutation, altering its affinity for VCP but minimizing the risk of disturbing other aspects of its structure or function. We introduced the R10A mutation, which weakens VCP binding in vitro, and expressed it in transgenic mice. R10AWld(S) fails to co-immunoprecipitate VCP from mouse brain, and only occasionally and faintly accumulates in nuclear foci for which VCP binding is necessary but not sufficient. Surprisingly however, axon protection remains robust and indistinguishable from that in spontaneous Wld(S) mice. We suggest that either N16 has an additional, VCP-independent function in mammals, or that the phenotype requires only weak VCP binding which may be driven forwards in vivo by the high VCP concentration.
Assuntos
Adenosina Trifosfatases/genética , Adenosina Trifosfatases/metabolismo , Proteínas de Ciclo Celular/genética , Proteínas de Ciclo Celular/metabolismo , Proteínas do Tecido Nervoso/genética , Proteínas do Tecido Nervoso/metabolismo , Nicotinamida-Nucleotídeo Adenililtransferase/genética , Nicotinamida-Nucleotídeo Adenililtransferase/metabolismo , Degeneração Walleriana/genética , Degeneração Walleriana/metabolismo , Animais , Axônios/metabolismo , Sítios de Ligação/genética , Sobrevivência Celular/genética , Citoproteção/genética , Camundongos , Camundongos Transgênicos , Mutação de Sentido Incorreto/genética , Ligação Proteica/genética , Estrutura Terciária de Proteína/genética , Proteína com Valosina , Degeneração Walleriana/fisiopatologiaRESUMO
The efficiency of preventive administration of silymarin and of silymarin medication were tested in dogs suffering from CCl4 intoxication of liver. Sixteen dogs of the Beagle breed at the age of 8 to 10 months and of the weight 11.5 to 14.0 kg were divided into four groups with four animals each. Those groups were administered per os a single dose of CCl4, 0.35 ml per kg liveweight contained in sunflower oil. The intact control groups was given sunflower oil free of any additive. Silymarin was administered per os in the form of suspension in the Dorfman reagent twice a day at the dose of 100 mg per kg. Silymarin was administered to the animals of the treated group four days after intoxication, to those of the preventively treated group four days before intoxication. The intact control group and the CCl4 intoxicated control were administered the pure Dorfman reagent. Pure CCl4 induced a significant increase in the AST and ALT activity in 12 and 24 hours after administration, and histological lesions in the liver--vacuolization of hepatocytes and necrobiosis of nuclei. The curative effects of silymarin on these changes were low. The protective effects of silymarin were manifested by the significantly lower AST and ALT activities in the 12th and 24th hour of the trial and by the insignificantly lower extent of lesions in liver parenchyma if compared with the control CCl4 intoxicated group.